Anticonvulsants Can Alter Irinotecan Metabolism

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

SAN ANTONIO-Enzyme-inducing antiepileptic drugs (EIAEDs) can significantly alter the metabolism of irinotecan (Camptosar) and should be taken into consideration when treating patients for brain tumors, according to John G. Kuhn, PharmD. Dr. Kuhn is professor of Pharmacology and Medicine at the University of Texas Health Sciences Center in San Antonio, Texas. He discussed data on irinotecan pharmacokinetics from an ongoing North American Brain Tumor Consortium (NABTC) phase I study.

SAN ANTONIO—Enzyme-inducing antiepileptic drugs (EIAEDs) can significantly alter the metabolism of irinotecan (Camptosar) and should be taken into consideration when treating patients for brain tumors, according to John G. Kuhn, PharmD. Dr. Kuhn is professor of Pharmacology and Medicine at the University of Texas Health Sciences Center in San Antonio, Texas. He discussed data on irinotecan pharmacokinetics from an ongoing North American Brain Tumor Consortium (NABTC) phase I study.

Irinotecan is metabolized via CYP3A4 to less active oxidative metabolites and bioactivated in the liver and intestine by carboxylesterases to the active SN-38 metabolite. Dr. Kuhn said the NABTC study was designed to determine the maximum tolerated dose of irinotecan given every 3 weeks to patients who were taking EIAEDs and to patients who were not taking such drugs. A phase II study will determine efficacy in progressive or recurrent primary gliomas.

Inducing and Noninducing Drugs Are Tested

The EIAEDs include phenytoin (Dilantin), phenobarbital (Donnatal), and carbamazepine (Tegretol). The noninducing AEDs include gabapentin (Neurontin), valproic acid (Depakene), levetiracetam (Keppra), topiramate (Topamax), lamotrigine (Lamictal), zonisamide (Zonegran), and tiagabine (Gabitril). Patients not on EIAEDs (n = 34, 22 evaluable) were treated with irinotecan 350 mg/m² IV over 90 minutes with no dose escalations. Patients on EIAEDs (n = 48, 34 evaluable) were treated with irinotecan at 350 mg/m² with dose escalations in 50 mg/m² increments.

"In the EIAEDs group, the dose-limiting toxicity was grade 3 diarrhea at the 800 mg/m² dose level. The phase II dose will be 750 mg/m² every 3 weeks. Clearance of irinotecan was about twofold higher in patients taking these drugs, and there was a dramatic decrease in the level of the active metabolite SN-38," Dr. Kuhn said. "Non-EIAEDs with or without steroids had little effect on irinotecan metabolism and excretion. Gabapentin, although not an enzyme-inducing agent, had a greater than expected effect on irinotecan clearance."

Related Videos
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Stacey A. Cohen, MD, and Daniel H. Ahn, DO, presenting slides
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
4 KOLs are featured in this panel.
4 KOLs are featured in this panel.
Related Content